Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 01:47PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.58 Insider Own11.58% Shs Outstand5.18M Perf Week2.75%
Market Cap3.78M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float4.58M Perf Month0.95%
Income-16.72M PEG- EPS next Q-0.52 Inst Own2.47% Short Float / Ratio0.88% / 2.98 Perf Quarter-24.39%
Sales4.62M P/S0.82 EPS this Y44.33% Inst Trans1.73% Short Interest0.04M Perf Half Y-30.90%
Book/sh-0.32 P/B- EPS next Y62.96% ROA-123.77% Target Price33.50 Perf Year-54.68%
Cash/sh0.40 P/C1.83 EPS next 5Y- ROE-321.20% 52W Range0.65 - 1.93 Perf YTD-43.40%
Dividend- P/FCF- EPS past 5Y75.13% ROI- 52W High-62.20% Beta-0.71
Dividend %- Quick Ratio0.58 Sales past 5Y-11.85% Gross Margin26.96% 52W Low12.25% ATR0.05
Employees38 Current Ratio0.58 Sales Q/Q-100.00% Oper. Margin-312.10% RSI (14)48.26 Volatility6.38% 6.94%
OptionableNo Debt/Eq- EPS Q/Q38.02% Profit Margin-361.57% Rel Volume1.03 Prev Close0.75
ShortableYes LT Debt/Eq- EarningsAug 15 BMO Payout- Avg Volume13.50K Price0.73
Recom1.00 SMA202.85% SMA50-10.04% SMA200-24.18% Volume10,692 Change-2.59%
Nov-14-23 04:30PM
Nov-07-23 08:30AM
Oct-23-23 08:30AM
Sep-27-23 08:30AM
Aug-30-23 07:09AM
08:30AM Loading…
Aug-17-23 08:30AM
Aug-15-23 08:30AM
Aug-01-23 08:30AM
Jul-24-23 08:15AM
Jun-14-23 10:30AM
Jun-05-23 08:15AM
May-16-23 08:00AM
May-12-23 07:20AM
May-02-23 04:30PM
05:46PM Loading…
Apr-21-23 05:46PM
Apr-18-23 08:45AM
Mar-21-23 08:35AM
Mar-15-23 09:05AM
Mar-09-23 08:30AM
Mar-08-23 08:05AM
Feb-01-23 09:05AM
Jan-24-23 09:00AM
Jan-23-23 09:02AM
Jan-10-23 09:00AM
Jan-05-23 09:00AM
Dec-12-22 08:30AM
Dec-07-22 09:10AM
Dec-01-22 07:11AM
09:00AM Loading…
Nov-22-22 09:00AM
Nov-17-22 06:12AM
Nov-15-22 07:30AM
Oct-19-22 09:00AM
Oct-18-22 09:00AM
Oct-06-22 08:00AM
Sep-14-22 05:02PM
Aug-25-22 06:45AM
Aug-18-22 09:15AM
Aug-16-22 07:30AM
Aug-01-22 08:30AM
Jul-06-22 09:00AM
Jun-14-22 09:00AM
Jun-07-22 09:04AM
Jun-06-22 06:10AM
Jun-02-22 09:00AM
May-26-22 09:15AM
May-20-22 09:15AM
May-13-22 06:00AM
May-10-22 09:17AM
May-03-22 02:24PM
Apr-29-22 09:15AM
Apr-18-22 06:25AM
Apr-12-22 10:15AM
Apr-05-22 09:15AM
Apr-01-22 08:00AM
Mar-30-22 09:15AM
Mar-22-22 09:15AM
Mar-15-22 09:15AM
Feb-22-22 09:15AM
Feb-15-22 09:15AM
Feb-01-22 09:15AM
Jan-18-22 09:15AM
Dec-14-21 09:18AM
Dec-01-21 03:25PM
Nov-29-21 03:50PM
Nov-22-21 10:23AM
Nov-15-21 09:00AM
Oct-19-21 09:00AM
Sep-15-21 07:30AM
Sep-08-21 07:30AM
Aug-31-21 06:22AM
Aug-23-21 09:58AM
Aug-17-21 10:01AM
Jul-14-21 07:30AM
Jul-07-21 10:37AM
Jun-08-21 07:30AM
Jun-02-21 07:30AM
May-19-21 07:30AM
May-18-21 02:10PM
May-14-21 01:35PM
Apr-26-21 07:00AM
Apr-19-21 01:16PM
Apr-06-21 09:30AM
Mar-18-21 08:30AM
Mar-09-21 08:30AM
Mar-08-21 08:30AM
Mar-01-21 08:30AM
Jan-26-21 09:00AM
Dec-30-20 11:16AM
Dec-22-20 09:00AM
Dec-18-20 03:07PM
Dec-16-20 10:25AM
Dec-15-20 09:00AM
Dec-08-20 09:00AM
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.